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Abstract. The mosquito-borne Inkoo virus (INKV) is a member of the California serogroup in the family Bunyaviridae,
genus Orthobunyavirus. These viruses are associated with fever and encephalitis, although INKV infections are not
usually reported and the incidence is largely unknown. The aim of the study was to determine the prevalence of anti-
INKV antibodies and associated risk factors in humans living in northern Sweden. Seroprevalence was investigated
using the World Health Organization Monitoring of Trends and Determinants in Cardiovascular Disease study, where
a randomly selected population aged between 25 and 74 years (N = 1,607) was invited to participate. The presence of
anti-INKV IgG antibodies was determined by immunofluorescence assay. Seropositivity for anti-INKV was significantly
higher in men (46.9%) than in women (34.8%; P < 0.001). In women, but not in men, the prevalence increased some-
what with age (P = 0.06). The peak in seropositivity was 45–54 years for men and 55–64 years for women. Living in
rural areas was associated with a higher seroprevalence. In conclusion, the prevalence of anti-INKV antibodies was
high in northern Sweden and was associated with male sex, older age, and rural living. The age distribution indicates
exposure to INKV at a relatively early age. These findings will be important for future epidemiological and clinical
investigations of this relatively unknown mosquito-borne virus.
INTRODUCTION
Mosquito-borne viruses cause a variety of clinical syndromes
in humans, and they include members of the Togaviridae,
Flaviviridae, and Bunyaviridae. The genus Orthobunyavirus
in the Bunyaviridae family has a growing number of strains.
Among them, the viruses in the California serogroup are
commonly found in the northern hemisphere, particularly in
North America, although some―such as Inkoo virus (INKV),
Tahyna virus (TAHV), and Snowshoe hare virus (SSHV) or the
closely related Chatanga virus―are also present in Europe.1–3
La Crosse virus of the North American California serogroup is
the most well known, causing encephalitis and meningitis in
children.4 The European TAHV has been associated with an
influenza-like illness with signs of meningoencephalitis, although
not as severe.
INKV is known to circulate in northern Europe and Russia.5–9
It has been isolated from Ochlerotatus communis mosquitoes in
Finland, Sweden, and Russia, and fromOchlerotatus hexodontus
and Ochlerotatus punctor in Russia.10–12 Disease associated
with INKV infection has not been extensively investigated, but
in Russia, the virus has been found to be associated with
seasonal fevers (May–September) and infection of the brain
(aseptic meningitis, meningoencephalitis, or encephalitis) and
even chronic neurological infections.13–15 Recently, in a study
from Finland, acute INKV infection was diagnosed in patients
with febrile illness.9 The frequency of clinical INKV infection
is unknown. However, in Finland, the proportion of the popu-
lation with anti-INKV IgG antibodies is high: 51% of those
tested had anti-INKV IgG antibodies.9 Other studies have
shown that INKV infection may be present in Alaska but
probably not in the European Tyrol Alps.8,16 Interestingly, the
seroprevalence in Finland has increased since the 1960s, when
24% of those tested were seropositive for anti-INKV.17
The degree of exposure of the human population to INKV
infection in Sweden is not known, so we wanted to investi-
gate the prevalence of anti-INKV IgG antibodies. In this
large randomized, stratified, and population-based survey in
northern Sweden, we also investigated possible associated
risk factors.
MATERIALS AND METHODS
Survey participants. In this study, we used data from the
northern Sweden component of the World Health Organization
Monitoring of Trends and Determinants in Cardiovascular
Disease (WHO MONICA) study.18 Between January and
April 2009, a population-based survey was conducted. Subjects
aged 25–74 years in the two most northern counties of Sweden
(target population 312,000) were randomly selected from pop-
ulation registers and stratified according to age and gender.
Thus, for each 10-year age group and starting from the youn-
gest age group of 25–34 years, 250 men and 250 women were
invited to participate. Details of sampling and selection have
been presented elsewhere.18
Of the 2,500 subjects invited, a total of 1,729 participated
(69.2%) in the MONICA study in northern Sweden, which
was used in the screening for anti-INKV IgG antibodies.
Data on individuals who declined participation have been
published.18 The lowest participation rates were found in the
age group 25–34 years: 50.4% in men and 59.6% in women.
The corresponding proportions for the age group 35–44 years
were 68.4% and 70.8%, for the age group 45–54 years were
67.6% and 70.8%, and for the age group 55–64 years were
76.0% and 75.2%. In the oldest age group, 65–74 years, partic-
ipation was 78.8% and 74% in men and women, respectively.18
Serological samples from 7.4% of subjects were missing.
Thus, valid data were available for 1,607 subjects: 50.7% men
and 49.3% women.
The measurement procedures included blood pressure mea-
sured twice in a sitting position with an interval of 5 minutes.
Subjects were weighed on an electronic scale. The highest
level of education attained was classified as 1) primary school
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or secondary school (0–12 years of school) or 2) university
studies. Regular smokers smoked at least one cigarette a
day; all other subjects were considered to be nonsmokers.
Subjects who answered yes to the question, “Do you have
diabetes mellitus?” or the question, “Have you been treated
for high blood pressure in the past two weeks” in the ques-
tionnaire were reported as having “known diabetes” and
“hypertension.” Subjects who owned a farm were reported
as being “farmers.”
The study was approved by the Regional Ethical Review
Board, Umeå, and all subjects gave informed consent.
Immunofluorescence assay for detection of anti-INKV IgG.
Serum samples obtained from the participants were stored at
−80°C before analysis. Anti-INKV IgG antibodies were
detected using a previously validated anti-INKV IgG immu-
nofluorescence assay (IFA).9 In brief, slides with acetone-fixed
Vero E6 cells, 30% of which had been infected with INKV,
were incubated with serum at a dilution of 1/20 for 30 minutes
at 37°C and then washed with cold phosphate-buffered saline
(PBS). The cells were stained with fluorescein isothiocyanate–
conjugated antihuman IgG (Jackson ImmunoResearch Labo-
ratories, West Grove, PA) for 30 minutes at 37°C, washed with
PBS, and examined with a fluorescence microscope. A posi-
tive fluorescence signal from 30% of the cells (with 70% of
the cells negative) was required for a positive result.
Neutralization assay. A subset of sera (N = 90) with nega-
tive, weakly positive, or strongly positive INKV IgG results
from the IFA were verified with a neutralization assay to
determine whether the IgG antibodies were specific to INKV,
TAHV, or SSHV.9 In brief, serially diluted serum samples
were mixed with INKV, TAHV, and SSHV (20 μL of a 500–
1,000 plaque forming units/mL suspension) and incubated for
1 hour at 37°C before infection of Vero E6 cells. The neutrali-
zation titer was defined as the highest dilution to inhibit the
cytopathic effect (CPE). If inconsistency was observed
between IFA results and CPE neutralization results, plaque
reduction neutralization test (PRNT) was used to confirm the
titers by using a reduction in plaque count of 50% as the neu-
tralization endpoint.3
Statistics. Differences between groups were tested with t test
or χ2 test, and means and proportions were reported. When
accounting for differences in sex and age between groups,
general linear models were used. All P values < 0.05 were
considered significant.
RESULTS
The proportion of subjects who were seropositive for INKV
IgG was 40.9%, and it was more common in men (46.9%)
than in women (34.8%; P < 0.001). The proportion of men
who were seropositive varied between the different age
groups (P = 0.046, χ2 test) but there was no linear relationship
with increasing age (P = 0.6, χ2, linear-by-linear association
test). In women, the prevalence increased somewhat with age
(P = 0.06, χ2, linear-by-linear) (Figure 1). There was a peak in
seropositivity in the age group 45–54 years in men and in the
age group 55–64 years in women (Figure 1). There was no sig-
nificant difference between the mean age of seropositive sub-
jects and the mean age of seronegative subjects, and this also
applied to men and women compared separately.
Living in smaller communities or rural areas was associ-
ated with a higher prevalence of seropositivity (P < 0.001)
(Table 1). This pattern was evident in all 10-year age groups,
and the observation was statistically significant in ages of
45 years and higher (P < 0.03). No other background factors
or prevalent disease showed any relationship with previous
INKV infection. In an analysis taking gender into account,
we found no differences in seropositivity for variables such
as level of education, living on a farm, diabetes, and myalgia
or arthralgia in either sex with the exception of men living
on a small farm (29.4% seropositivity compared with 47.7%
in men not living on a farm; P = 0.0036). However, the 95%
confidence interval for this 18.2% difference in prevalence
was 1.2–32%.
Seropositive subjects generally had higher body mass index,
waist circumference, systolic and diastolic blood pressure, and
serum creatinine (data not shown). After adjusting for the
differences in sex and age, no differences between groups
remained significant.
Because of the large number of anti-INKV antibody posi-
tives, a subset of serum samples (64 positive and 26 negative)
was selected for verification of the anti-INKV IgG IFA results
by a neutralization assay. The assay involved neutralization
FIGURE 1. Proportion of anti-INKV IgG antibody positive sub-
jects in Northern Sweden, according to gender and age.
TABLE 1
Anti-INKV seropositivity according to demography, lifestyle, and
prevalent disease
Variable
Proportion of population
with anti-INKV(%)
Size of residential area,
no. of inhabitants
> 15,000 35.1
> 1,000 47.3
< 1,000 49.2
Level of education No university studies 41.0
University studies 40.1
Small farm No 41.1
Yes 37.5
Large farm No 40.9
Yes 62.5
Daily smoker Yes 39.4
No 41.3
Previous myocardial
infarction
Yes 40.0
No 40.9
Previous stroke Yes 34.9
No 41.1
Diabetes Yes 45.5
No 40.8
Myalgia No 41.1
Yes 38.8
Arthralgia No 40.8
Yes 42.9
Steroid treatment Yes 38.3
No 41.1
INKV = Inkoo virus. All P values were > 0.2, except size of residential area (P < 0.001).
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of three viruses from the California serogroup: INKV, TAHV,
and SSHV. Altogether, 62 of 64 (97%) of the anti-INKV IgG
IFA–positive samples, either strongly or weakly positive, spe-
cifically neutralized INKV and all anti-INKV IFA–negative
serum samples were confirmed to be negative (Supplemental
Table 1). As expected, there was some cross-reactivity with
TAHV and SSHV. However, anti-INKV titers were approxi-
mately 4-fold higher than the antibody titers to the other
viruses tested (on average 3.6 and 4.2 higher than for SSHV
and TAHV, respectively), with geometrical mean titers of
77 for anti-INKV, 28 for anti-SSHV, and 24 for anti-TAHV).
One IFA-positive sample that did not neutralize any of the
three viruses was observed, and interestingly, one of the weak
IFA-positive samples had a high neutralization titer to TAHV
only (Supplemental Table 1). Of the anti-INKV positive sam-
ples that neutralized INKV, 11 were further verified by PRNT,
and they were all confirmed to be positive (data not shown).
DISCUSSION
There are numerous kinds of mosquito-borne viruses that
may be a threat to public health. Members of the California
serogroup are less well known, and there have been very few
studies of the epidemiological and clinical properties of the
European orthobunyavirus INKV. In this study, we found a
high prevalence of anti-INKV antibodies in a population-
based cohort from northern Sweden, and more so in men than
in women. A similarly high seroprevalence has been shown
in a previous study in Finland.9
The strength of this study was the use of a large randomized
and stratified population-based sample. The only background
variable that was significantly associated with seropositivity
was living in small communities or rural areas, which suggests
more exposure to mosquitoes. All other associations noted
could be explained by age and sex differences.
We used a previously validated9 serological IFA to detect
anti-INKV IgG antibodies. In a subset of samples the results
were verified with a neutralization assay, which confirmed
the high specificity and sensitivity of the anti-INKV IgG IFA
test used for screening.9
We cannot completely rule out cross-reactivity to other
members of the California serogroup, but positive samples
had higher neutralization titers to INKV than to TAHV and
SSHV, indicating the presence of anti-INKV antibodies. It is
possible that some individuals had undergone infections by
other orthobunyaviruses of the California serogroup, either
through travel or locally. Interestingly, a SSHV-like Chatanga
virus has been identified in the neighboring country Finland.3
Intriguingly, the high prevalence of anti-INKV antibodies is
not reflected by recognized cases of human infections. The high
proportion of seropositive individuals already in the younger
age group, 25–35 years, suggests that there is relatively early
exposure to this mosquito-borne virus. Interestingly, for the
mosquito-borne Sindbis virus, which is also present in northern
Sweden, we found that virus antibodies were uncommon in
young people, with no age-dependent increase, suggesting a
recent introduction of Sindbis virus and increase in this
region.19 Human INKV infection may be subclinical, and the
majority of clinical cases are probably not recognized. In
Finland, acute INKV infection has been detected in some
patients with suspected viral infections of the central nervous
system, but the infection appears to be mild or under-
diagnosed.9 It is notable, however, that at least one-third of
all viral meningitis and encephalitis in Sweden and Finland is
of unknown etiology.20,21
Our results indicate that INKV is widespread and highly
endemic in northern Sweden, which may be explained in
part by the fact that two of the suggested mosquito vectors,
Ochlerotatus communis and Ochlerotatus punctor are very
common22,23 and that the exposure to mosquitoes, in general,
is high in this region.
CONCLUSIONS
In conclusion, the high prevalence of anti-INKV antibodies
indicates that this mosquito-borne viral pathogen has been
very common in northern Sweden. The seroprevalence was
found to be higher in men and in rural areas. These findings
draw attention to the possible impact of this infection, which is
still relatively unknown to the medical community. However,
the clinical importance of INKV requires further studies of
febrile cases during the mosquito season in endemic areas. More
arbovirus studies are also needed to determine the factors
that are important for its circulation and human infection.
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